Liquidia Corp
LQDA13.100USD
+0.270+2.10%
Cierre 06/27, 16:00（ET）Cotizaciones retrasadas 15 min
1.12BCap. mercado
PérdidaP/E TTM
Más Datos de Liquidia Corp Compañía
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Información de la empresa
Símbolo de cotizaciónLQDA
Nombre de la empresaLiquidia Corp
Fecha de salida a bolsaJul 26, 2018
Fundada en2020
Director ejecutivoDr. Roger A. Jeffs, Ph.D.
Número de empleados157
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 26
Dirección419 Davis Drive
CiudadMORRISVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27560
Teléfono19193284400
Sitio Webhttps://www.liquidia.com/
Símbolo de cotizaciónLQDA
Fecha de salida a bolsaJul 26, 2018
Fundada en2020
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.13M
+1.85%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
372.72K
+2.59%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
266.92K
+3.92%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
216.08K
+4.00%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.93K
+5.42%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
146.34K
+10.17%
Mr. Damian Degoa
Mr. Damian Degoa
Independent Director
Independent Director
66.11K
+38.55%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
50.40K
+57.49%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
18.40K
--
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
18.40K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.13M
+1.85%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
372.72K
+2.59%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
266.92K
+3.92%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
216.08K
+4.00%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.93K
+5.42%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
146.34K
+10.17%
Desglose de ingresos
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
14.00M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Caligan Partners, LP
9.50%
Manning (Paul B.)
7.21%
BlackRock Institutional Trust Company, N.A.
4.91%
Farallon Capital Management, L.L.C.
4.67%
The Vanguard Group, Inc.
4.04%
Other
69.67%
Accionistas
Accionistas
Proporción
Caligan Partners, LP
9.50%
Manning (Paul B.)
7.21%
BlackRock Institutional Trust Company, N.A.
4.91%
Farallon Capital Management, L.L.C.
4.67%
The Vanguard Group, Inc.
4.04%
Other
69.67%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
30.69%
Investment Advisor/Hedge Fund
15.97%
Investment Advisor
12.67%
Individual Investor
11.55%
Research Firm
3.48%
Corporation
2.69%
Private Equity
1.78%
Bank and Trust
0.26%
Pension Fund
0.21%
Other
20.70%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
344
64.23M
75.45%
-9.89M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
2023Q3
236
40.52M
62.49%
-5.87M
2023Q2
223
41.12M
63.56%
-6.16M
2023Q1
214
42.01M
65.00%
-5.41M
2022Q4
210
41.20M
63.89%
-7.92M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Caligan Partners, LP
8.12M
9.52%
--
--
Dec 31, 2024
Manning (Paul B.)
6.15M
7.21%
+316.72K
+5.43%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
4.18M
4.9%
+416.76K
+11.07%
Dec 31, 2024
Farallon Capital Management, L.L.C.
3.29M
3.86%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
3.55M
4.16%
+115.37K
+3.36%
Dec 31, 2024
Findell Capital Management LLC
3.08M
3.61%
-113.54K
-3.56%
Dec 31, 2024
Opaleye Management Inc.
1.70M
1.99%
--
--
Dec 31, 2024
Jeffs (Roger A)
2.19M
2.56%
+206.98K
+10.46%
Jan 14, 2025
Legend Aggregator LP
1.86M
2.18%
-5.32M
-74.10%
Dec 31, 2024
State Street Global Advisors (US)
1.81M
2.12%
-363.63K
-16.72%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
Invesco Pharmaceuticals ETF
2.76%
Invesco Dorsey Wright Healthcare Momentum ETF
1.97%
SPDR S&P Pharmaceuticals ETF
1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.11%
ALPS Medical Breakthroughs ETF
1.08%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
iShares U.S. Pharmaceuticals ETF
0.3%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
SPDR S&P Kensho New Economies Composite ETF
0.22%
iShares Micro-Cap ETF
0.21%
Ver más
Invesco Pharmaceuticals ETF
Proporción2.76%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.97%
SPDR S&P Pharmaceuticals ETF
Proporción1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.11%
ALPS Medical Breakthroughs ETF
Proporción1.08%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.01%
iShares U.S. Pharmaceuticals ETF
Proporción0.3%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.27%
SPDR S&P Kensho New Economies Composite ETF
Proporción0.22%
iShares Micro-Cap ETF
Proporción0.21%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
